Movement Disorders

Home >> Publications >> Journal >> Movement Disorders

Cellular Prion Protein Mediates α-Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo

Authors Thom T, Schmitz M, Fischer AL, Correia A, Correia S, Llorens F, Pique AV, Möbius W, Domingues R, Zafar S, Stoops E, Silva CJ, Fischer A, Outeiro TF, Zerr I Journal Movement Disorders Citation Mov Disord. 2021 Aug 27. Abstract Background The cellular prion protein (PrPC) is a membrane-bound,
Learn More

α-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson’s Disease

Authors Stuendl A, Kraus T, Chatterjee M, Zapke B, Sadowski B, Moebius W, Hobert MA, Deuschle C, Brockmann K, Maetzler W, Mollenhauer B, Schneider A Journal Movement Disorders Citation Mov Disord. 2021 May 18. Abstract Background: Extracellular vesicles are small vesicles that are released from many cells, including neurons. α-Synuclein
Learn More

Dysfunction of RAB39B-Mediated Vesicular Trafficking in Lewy Body Diseases

Authors Koss DJ, Campesan S, Giorgini F, Outeiro TF Journal Movement Disorders Citation Mov Disord. 2021 May 3. Abstract Intracellular vesicular trafficking is essential for neuronal development, function, and homeostasis and serves to process, direct, and sort proteins, lipids, and other cargo throughout the cell. This intricate system of membrane
Learn More

Cancer and Parkinson’s Disease: Common Targets, Emerging Hopes

Authors Filippou PS, Outeiro TF Journal Movement Disorders Citation Mov Disord. 2020 Dec 21. Abstract Cancer and neurodegeneration are two major leading causes of morbidity and death worldwide. At first sight, the two fields do not seem to share much in common and, if anything, might be placed on opposite
Learn More

From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson’s Disease

Authors Outeiro TF, Heutink P, Bezard E, Cenci AM Journal Movement Disorders Citation Mov Disord. 2020 Nov 16. Abstract Parkinson’s disease (PD) is primarily known as a movement disorder because of typical clinical manifestations associated with the loss of dopaminergic neurons in the substantia nigra. However, it is now widely
Learn More

Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy

Authors Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N Journal Movement Disorders Citation Mov Disord. 2019 Feb;34(2):255-263. Abstract BACKGROUND: MSA is a fatal neurodegenerative disease characterized by autonomic failure and severe motor impairment. Its main pathological hallmark is the accumulation of alpha-synuclein
Learn More

Open Positions